Cancer Research Translational Cancer Medicine 2008: Cancer Clinical Trials and Personalized Medicine  Joint Metastasis Research Society-AACR Conference on Metastasis
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation

[Cancer Research 57, 1962-1969, May 15, 1997]
© 1997 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Lansing, T. J.
Right arrow Articles by Gilmer, T. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lansing, T. J.
Right arrow Articles by Gilmer, T. M.

Mutational Activation of pp60c-src Leads to a Tumorigenic Phenotype in a Preneoplastic Syrian Hamster Embryo Cell Line

Timothy J. Lansing, Bartel F. Turk, Steven B. Kanner and Tona M. Gilmer1

Department of Cancer Biology, Glaxo Wellcome Research and Development, Research Triangle Park, North Carolina 27709 [T. J. L., B. F. T., T. M. G.]; and Bristol-Myers Squibb Pharmaceutical Research Institute, Seattle, Washington 98121 [S. B. K.]

Previous studies indicated that overexpression of wild-type avian c-src cannot induce neoplastic transformation of NIH 3T3 cells. In this study, we isolated and characterized novel spontaneously derived transforming mutants of avian pp60c-src from a Syrian hamster embryo-derived cell line, 10W, transfected with the avian c-src gene. Seventeen independently derived transfected 10W cell clones were injected into athymic nude mice. After a latency period, tumors eventually arose and were established in culture. The tumorigenic phenotype was always accompanied by the presence of the avian c-src DNA and functional expression of pp60c-src. However, most of the tumor-derived cell lines expressed an electrophoretically altered form of pp60c-src, suggesting mutations in src. Consistent with this hypothesis, DNAs isolated from the tumor-derived lines, but not the parental 10W cell lines, morphologically transformed NIH 3T3 cells in a focus-forming assay. We characterized pp60c-src in detail from three of the tumor-derived lines: 4AT, 4BT, and E2T. Two of these lines contained mutations within the exogenous c-src coding region. Line 4AT has an internal repeat of 29 amino acids immediately following Gln-513, which disrupts the spacing between the end of the kinase domain and Tyr-527, the negative regulatory site in pp60c-src. Line 4BT has a 5-bp deletion following Phe-520, which results in loss of Tyr-527. However, the DNA sequence of the coding region of pp60c-src from a third line, E2T, was completely wild type. Cyanogen bromide cleavage analyses of the altered pp60c-src from lines 4AT and 4BT showed that Tyr-527, the site of negative regulation of c-src, is not phosphorylated, but Tyr-416, the site of in vitro autophosphorylation, is phosphorylated. However, in line E2T, Tyr-527 was phosphorylated, and Tyr-416 was phosphorylated to a lesser extent. Additionally, two proteins that indicate activation of src, p85 cortactin and p120cas, are phosphorylated in at least six of the tumor-derived cell lines, although to a lesser extent in line E2T. These results suggest that dephosphorylation of Tyr-527 and phosphorylation of Tyr-416 correlate with activation of pp60c-src in the tumor-derived lines 4AT and 4BT, respectively. However, in line E2T, the high levels of pp60c-src, in combination with a partial activation of the pp60c-src protein as indicated by phosphorylation of Tyr-416, appear to be involved in the neoplastic process, rather than mutation.

1 To whom requests for reprints should be addressed, at RCII, Room 806, Department of Cancer Biology, Glaxo Wellcome Research and Development, Research Triangle Park, NC 27709. Phone: (919) 483-6335; Fax: (919) 315-8597.

Received 1/30/96. Accepted 3/24/97.




This article has been cited by other articles:


Home page
Cancer Res.Home page
Y. Daigo, Y. Furukawa, T. Kawasoe, H. Ishiguro, M. Fujita, S. Sugai, S. Nakamori, G.-J. Liefers, R. A. E. M. Tollenaar, C. J. H. van de Velde, et al.
Absence of Genetic Alteration at Codon 531 of the Human c-src Gene in 479 Advanced Colorectal Cancers from Japanese and Caucasian Patients
Cancer Res., September 1, 1999; 59(17): 4222 - 4224.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Cell Growth & Differentiation
Copyright © 1997 by the American Association for Cancer Research.